687 related articles for article (PubMed ID: 21276815)
1. The use of long acting β₂-agonists, alone or in combination with inhaled corticosteroids, in chronic obstructive pulmonary disease (COPD): a risk-benefit analysis.
Cave AC; Hurst MM
Pharmacol Ther; 2011 May; 130(2):114-43. PubMed ID: 21276815
[TBL] [Abstract][Full Text] [Related]
2. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease.
Nannini LJ; Poole P; Milan SJ; Kesterton A
Cochrane Database Syst Rev; 2013 Aug; 2013(8):CD006826. PubMed ID: 23990350
[TBL] [Abstract][Full Text] [Related]
3. The impact of inhaled corticosteroid and long-acting beta-agonist combination therapy on outcomes in COPD.
Hanania NA
Pulm Pharmacol Ther; 2008; 21(3):540-50. PubMed ID: 18280761
[TBL] [Abstract][Full Text] [Related]
4. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study.
Larsson K; Janson C; Lisspers K; Jørgensen L; Stratelis G; Telg G; Ställberg B; Johansson G
J Intern Med; 2013 Jun; 273(6):584-94. PubMed ID: 23495860
[TBL] [Abstract][Full Text] [Related]
5. Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis.
Wang J; Nie B; Xiong W; Xu Y
J Clin Pharm Ther; 2012 Apr; 37(2):204-11. PubMed ID: 21740451
[TBL] [Abstract][Full Text] [Related]
6. Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS.
Latorre M; Novelli F; Vagaggini B; Braido F; Papi A; Sanduzzi A; Santus P; Scichilone N; Paggiaro P
Pulm Pharmacol Ther; 2015 Feb; 30():44-50. PubMed ID: 25445928
[TBL] [Abstract][Full Text] [Related]
7. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence.
Blais L; Forget A; Ramachandran S
Clin Ther; 2010 Jul; 32(7):1320-8. PubMed ID: 20678680
[TBL] [Abstract][Full Text] [Related]
8. Effects of inhaled corticosteroids /long-acting agonists in a single inhaler versus inhaled corticosteroids alone on all-cause mortality, pneumonia, and fracture in chronic obstructive pulmonary disease: A nationwide cohort study 2002-2013.
Cho KH; Kim YS; Linton JA; Nam CM; Choi Y; Park EC
Respir Med; 2017 Sep; 130():75-84. PubMed ID: 29206637
[TBL] [Abstract][Full Text] [Related]
9. Incidence of oral thrush in patients with COPD prescribed inhaled corticosteroids: Effect of drug, dose, and device.
Dekhuijzen PNR; Batsiou M; Bjermer L; Bosnic-Anticevich S; Chrystyn H; Papi A; Rodríguez-Roisin R; Fletcher M; Wood L; Cifra A; Soriano JB; Price DB
Respir Med; 2016 Nov; 120():54-63. PubMed ID: 27817816
[TBL] [Abstract][Full Text] [Related]
10. Effects of inhaled corticosteroids in monotherapy or combined with long-acting {beta}2-agonists on mortality among patients with chronic obstructive pulmonary disease.
Cyr MC; Beauchesne MF; Lemière C; Aaron SD; Blais L
Ann Pharmacother; 2010 Apr; 44(4):613-22. PubMed ID: 20233915
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis.
Baker WL; Baker EL; Coleman CI
Pharmacotherapy; 2009 Aug; 29(8):891-905. PubMed ID: 19637942
[TBL] [Abstract][Full Text] [Related]
12. [Triple therapy in chronic obstructive pulmonary disease].
Baloira A
Arch Bronconeumol; 2010; 46 Suppl 8():25-30. PubMed ID: 21334553
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy in asthma--fixed or variable dosing in different patients?
Lötvall J
Curr Med Res Opin; 2004 Nov; 20(11):1711-27. PubMed ID: 15537472
[TBL] [Abstract][Full Text] [Related]
14. Mono- and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD.
Ohar JA; Donohue JF
Semin Respir Crit Care Med; 2010 Jun; 31(3):321-33. PubMed ID: 20496301
[TBL] [Abstract][Full Text] [Related]
15. Survival among COPD patients using fluticasone/salmeterol in combination versus other inhaled steroids and bronchodilators alone.
Mapel DW; Nelson LS; Lydick E; Soriano J; Yood MU; Davis KJ
COPD; 2007 Jun; 4(2):127-34. PubMed ID: 17530506
[TBL] [Abstract][Full Text] [Related]
16. Comparison and optimal use of fixed combinations in the management of COPD.
Mensing M; Aalbers R
Int J Chron Obstruct Pulmon Dis; 2007; 2(2):107-16. PubMed ID: 18044682
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological basis and scientific rationale underlying the targeted use of inhaled corticosteroid/long-acting β2-adrenergic agonist combinations in chronic obstructive pulmonary disease treatment.
Pelaia G; Muzzio CC; Vatrella A; Maselli R; Magnoni MS; Rizzi A
Expert Opin Pharmacother; 2015; 16(13):2009-21. PubMed ID: 26194120
[TBL] [Abstract][Full Text] [Related]
18. LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes.
Hizawa N
Int J Chron Obstruct Pulmon Dis; 2015; 10():1093-102. PubMed ID: 26089659
[TBL] [Abstract][Full Text] [Related]
19. Treatment of persistent asthma with Symbicort (budesonide/formoterol inhalation aerosol): an inhaled corticosteroid and long-acting beta2-adrenergic agonist in one pressurized metered-dose inhaler.
Berger WE; Noonan MJ
J Asthma; 2010 May; 47(4):447-59. PubMed ID: 20528601
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD management.
Roberts M; Mapel D; Petersen H; Blanchette C; Ramachandran S
J Med Econ; 2011; 14(6):769-76. PubMed ID: 21942463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]